Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Endo divestiture of International Pharmaceuticals business
We are advising Endo on the transaction
Emerson €1 billion and $500 million notes offering
The investment-grade debt consists of three tranches of notes
Venture Global $1.75 billion IPO
We advised Venture Global on its IPO and NYSE listing
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Paychex $4.1 billion acquisition of Paycor HCM
We are advising Paychex on the transaction
Aptiv corporate reorganization
We advised Aptiv on the corporate reorganization
Merchants Bancorp $230 million preferred stock offering
The depositary shares represent an interest in 7.625% fixed rate non-cumulative perpetual preferred stock